Celldex Therapeutics Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Celldex is a clinical stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Visit www.celldex.com.
Current Price
$31.34
-3.42%Profile
Valuation (TTM)
Market Cap$2.09B
P/E-7.35
EV—
P/B3.96
Shares Out66.57M
P/Sales2408.99
Revenue$866000.00
EV/EBITDA—
Celldex Therapeutics Inc (CLDX) Stock News
CLDX Stock News & Headlines
Latest stock news and headlines for Celldex Therapeutics Inc (CLDX). Stay informed on earnings reports, analyst upgrades and downgrades, market-moving events, and company announcements.
Current stock price: $31.34. Market cap: $2.09B. Sector: Healthcare. Industry: Biotechnology. This page aggregates the latest news articles relevant to CLDX from financial news sources, helping investors stay current on events that may impact Celldex Therapeutics Inc's stock price.
News catalysts can drive significant short-term price movement. Earnings surprises, management changes, product launches, regulatory decisions, and analyst coverage changes all create opportunities and risks. Combine news monitoring with GoodMoat's fundamental analysis, quality scores, and valuation tools for a complete research workflow on Celldex Therapeutics Inc (CLDX).